STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGEN
  4. [Form 4] REPLIGEN CORP Insider Trading Activity

Repligen (RGEN) director Rohin Mhatre receives RSU and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Repligen Corp director Rohin Mhatre reported routine equity compensation awards. He received 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 5,014 shares after the grant.

He was also granted stock options for 2,239 shares of common stock at an exercise price of $103.38 per share. These options are exercisable starting on May 14, 2027 and expire on May 14, 2036. The restricted stock units and options each vest in full on the earlier of May 14, 2027 or the date of the next annual meeting of shareholders, which has not yet been determined.

Positive

  • None.

Negative

  • None.
Insider Mhatre Rohin
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,239 $0.00 --
Grant/Award Common Stock 995 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 2,239 shares (Direct, null); Common Stock — 5,014 shares (Direct, null)
Footnotes (1)
  1. Mr. Mhatre was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
RSU grant 995 units Restricted stock units awarded to director Rohin Mhatre
Shares held after grant 5,014 shares Common stock directly held after RSU award
Option grant size 2,239 options Stock options on common shares granted May 14, 2026
Option exercise price $103.38 per share Strike price for 2,239 stock options
Option exercisable date May 14, 2027 Date options become exercisable
Option expiration May 14, 2036 Expiration date of stock options
restricted stock units financial
"Mr. Mhatre was awarded 995 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 103.3800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of the Company's shareholders financial
"or the date of the next annual meeting of the Company's shareholders"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mhatre Rohin
(Last)(First)(Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026A995(1)A$0.005,014D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$103.3805/14/2026A2,23905/14/2027(2)05/14/2036Common Stock2,239$0.002,239D
Explanation of Responses:
1. Mr. Mhatre was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
/s/ Jennifer Carmichael (Attorney in Fact)05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Repligen (RGEN) director Rohin Mhatre report?

Director Rohin Mhatre reported routine equity compensation awards. He received 995 restricted stock units and stock options for 2,239 shares of Repligen common stock, all granted at no cash cost to him as part of his director compensation package.

How many Repligen (RGEN) shares does Rohin Mhatre hold after this Form 4?

After the restricted stock unit grant, Rohin Mhatre directly holds 5,014 shares of Repligen common stock. This total reflects his position following the award of 995 restricted stock units, which each represent a contingent right to receive one share upon vesting.

What are the key terms of Rohin Mhatre’s new stock options in Repligen (RGEN)?

Mhatre was granted options on 2,239 shares of Repligen common stock with an exercise price of $103.38 per share. The options become exercisable on May 14, 2027 and expire on May 14, 2036, providing a long-dated equity incentive.

When do Rohin Mhatre’s restricted stock units in Repligen (RGEN) vest?

The 995 restricted stock units vest in full on the earlier of May 14, 2027 or the date of Repligen’s next annual shareholder meeting. That meeting date has not yet been determined, so vesting could occur sooner if the meeting is held before May 14, 2027.

Are Rohin Mhatre’s awards in Repligen (RGEN) cash or equity based?

Both awards are equity-based. The 995 restricted stock units can only be settled in shares of Repligen common stock, and the 2,239 stock options give a right to buy shares at $103.38. No cash compensation figures appear in this Form 4 filing.

Does this Repligen (RGEN) Form 4 show any insider share sales by Rohin Mhatre?

The Form 4 shows only acquisitions through grants, not open-market sales. It reports 995 restricted stock units and 2,239 stock options awarded as compensation, with no transactions coded as sales or dispositions and no tax withholding entries disclosed.